BNB Plus Receives $1.2M Order For LineaDNA By Global Producer Of In Vitro Diagnostics

BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026.

The order was placed by a global manufacturer of in vitro diagnostics (IVDs) under an existing supply agreement. The Company has previously announced LineaDNA purchases by this customer, including a $600,000 USD follow-on order in July 2025. This latest order reflects the customer's decision to accelerate their procurement timeline, resulting in planned delivery within five months rather than the typical two-year cycle.

Inclusive of its recent $1.2M USD order, the Company expects to ship over $1.5M USD of LineaDNA to customers in the IVD and biotherapeutic markets in the first half of calendar year 2026.